Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Avelumab in Solid Tumors and Ovarian Cancer
NCT03558139Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- May 2018
- Primary completion
- Dec 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of magrolimab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC) and 1 more (3 arms), sponsored by Gilead Sciences. Primary endpoints: Dose Limiting Toxicities at 5 weeks, Treatment-Emergent Adverse Events up to 18.3 months and 1 more. Started May 2018; status: completed.
02
Drugs
magrolimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)solid tumor
Beyond the preview
Go deeper on NCT03558139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558139.